Trailblazers, iconoclasts and breakthrough artists are coming to the Endpoints biotech summit — please join us

Aviv Regev

When Aviv Regev closed out one long chapter of her life at the Broad and stepped into a new job as head of research and early development at Genentech four years ago, she set out to build a whole new approach to drug discovery on top of the broad base that had been in place for decades. Working with new AI and machine learning tools pioneered at the Broad, she’s been looking to blaze a new path in drug creation in search of the holy grail of the R&D world: A higher rate of significant success in the face of bleak — and expensive — historical reality.

Regev and I have had a chance to discuss this a few times along the way in her journey. And now we’ll be on stage at our parallel BIO event in San Diego in a few weeks to explore more about the most important issues driving the discussion in the multibillion-dollar R&D industry, which is grappling with a transformational technology.

Jami Rubin

She’s one in a long lineup of top biopharma execs coming to our annual biotech summit. I’m particularly happy to tell you that Jami Rubin, perhaps the single most outspoken biotech analyst of her time, now a biotech CFO, will be sitting down for a conversation with Executive Editor Drew Armstrong. Some of the most successful biotech execs in the industry will also be joining us to discuss what it is that separates the winners from the losers in the wake of a tough two-year downturn. And both Andrew Dunn and Amber Tong are steering their own panels on gene therapy and the uncertain future ahead for China biotechs.

You can get the full agenda here, along with a sign-up sheet for tickets to the event. In case you aren’t making the trip to BIO this year, we also offer free registration for subscribers who want to watch online.

I’ll be hanging around on site all day on June 3. As always, I’d encourage you to drop by and say hello and tell me a little about what you are doing. I’ve met quite a few biotech folks along the way in the last 22 years, and it’s always the face-to-face that left the most vivid impressions. You can also meet Armstrong and others on the Endpoints staff. Drop me a line in the meantime if you have any questions.